Will Biosimilars Meet the Market Similar Test?  That’s the question Rita Numerof, Ph.D. asks in her eyeforpharma Industry Insights column on August 1, 2014.  Today, branded biologics go to market with a variety of additional wrap-around services.  For example, patient education programs teach patients to use and store injectables, and compliance programs help physicians maximize outcomes.  Manufacturers also provide additional services supporting pharmacists and the supply chain.

Rita discusses how manufacturers of either biosimilar or branded biologics can successfully address the market similar challenge.  To what extent should producers of branded biologics modify their current programs?  For biosimilar makers, what programs are needed at launch and thereafter to meet the market similar test?  In her column, Rita outlines how to answer these and other critical questions as the U.S. prepares for its first biosimilars.